| Item type |
学術雑誌論文 / Journal Article(1) |
| タイトル |
|
|
タイトル |
A Case of Conversion Hepatectomy for Hepatocellular Carcinoma with Vascular Invasion after Atezolizumab-bevacizumab Treatment |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Hepatocellular carcinoma |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Immune checkpoinat inhibitor |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Conversion surgery |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 著者 |
Takada, Musashi
Tajima, Hidehiro
Noro, Takuji
Kawasaki, Keishi
Tatsuoka, Teppei
Okuyama, Takashi
Kusano, Yumi
Ban, Shinichi
Tamano, Masaya
Yoshitomi, Hideyuki
|
| 書誌情報 |
en : Dokkyo Medical Journal
巻 2,
号 4,
p. 315-322,
発行日 2023-12-25
|
| 記事種別 |
|
|
値 |
Case Report |
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
We report a hepatocellular carcinoma (HCC) case with vascular invasion successfully treated by conversion hepatectomy after treatment by atezolizumab-bevacizumab. A 74-year-old male patient was diagnosed with HCC and referred to our hospital. The tumor at the anterior section was 12.3 cm in diameter. It had invaded a portal vein branch of subsection 5 (S5) and peripheral branches of the middle hepatic vein. Serum alpha-fetoprotein (AFP) level was extremely high at 177408.3 ng/ml. The patient first received atezolizumab-bevacizumab treatment. After three cycles of atezolizumab-bevacizumab therapy, the tumor had decreased in size, the invasion into a portal and hepatic vein disappeared, the tumor enhancement completely vanished in the CT scan, and the tumor markers became within normal range. We decided to perform a conversion hepatectomy. The tumor was removed entirely by S5 partial resection, and pathological analyses showed a complete response to atezolizumab-bevacizumab treatment. There was no perioperative complication. The patient has survived for nine months without recurrence so far. Atezolizumab combined with bevacizumab might be an effective and appropriate option for the multidisciplinary treatment aiming for curative surgical resection. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Dokkyo Medical Society |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2436-522X |
| 書誌レコードID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12941861 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.51040/dkmj.2023-016 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
DKMJ-2-4-9.pdf (783 KB)
.png)
